Publication details

Prognostic Impact of Copeptin and Mid-Regional Pro-Adrenomedullin in Chronic Heart Failure with Regard to Comorbidities

Authors

ŠPINAROVÁ Lenka ŠPINAROVÁ Monika PÁVKOVÁ GOLDBERGOVÁ Monika ŠPINAR Jindřich PAŘENICA Jiří LUDKA Ondřej LÁBR Karel MALEK F. OSTADAL P. VONDRAKOVA D. TOMANDL Josef VEVERKOVÁ Jana LIPKOVÁ Jolana BENEŠOVÁ Klára JARKOVSKÝ Jiří

Year of publication 2018
Type Article in Periodical
Magazine / Source Journal of Cardiovascular & Diseases Diagnosis
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.4172/2329-9517.1000326
Keywords Chronic heart failure; AHEAD score; Copeptin; Midregional pro-adrenomedullin; Prognosis
Description The aim of the study is to evaluate the impact of new humoral substances: copeptin and mid- regional proadrenomedullin (MR-proADM) on one-year survival of patients with stable systolic chronic heart failure (CHF) and to compare them with AHEAD score assessing the comorbidities. The FAR NHL (FARmacology and NeuroHumoraL activation) registry is a database of patients with stable CHF (ejection fraction (EF) <50%) treated in specialized HF departments. AHEAD score is a simple bed-side mortality predictive model based on age and comorbidities. Primary endpoint after 1-year follow-up was: death or hospitalization for decompensation of HF or heart transplantation or LVAD implantation. To whole FAR NHL registry, a total amount of 1088 patients were included, in 552 of them the levels of copeptin and MR-proADM were available. Mean age was 65+12 years, mean EF was 31+9%. Patients without primary endpoint were assigned as group A (469 pts), those with the primary endpoint group B (83 pts). There were statistically significant differences between the groups in the levels of copeptin: group A median 15.9 pmol/l (3.4-50.9) vs group B 23.7 pmol/l(5.0-89.44) (p<0.001), MR-proADM: group A median 0.63 nmol/l(0.32-1.34) vs group B 0.74 nmol/l (0.4-1.94) (p<0.001). Relationship of AHEAD score to primary endpoint in the first year of follow-up was not significant, but within 24th month it reached statistical significance: p= 0.017. Patients with higher AHEAD score (more comorbidities) reached more often the primary end-point.

You are running an old browser version. We recommend updating your browser to its latest version.

More info